micro-community-banner
 
  • Saved

1yr
Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature - PubMed

Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37877303/

Cutaneous T-cell lymphoma (CTCL) is a rare hematologic malignancy that traditionally presents with cutaneous lesions, though metastases are not uncommon in progressive disease. We describe four cases of CTCL with...

Four CTCL cases with CNS involvement showed a median 5.4-year progression to metastasis. Survival post-metastasis averaged 160 days, with some remission after CNS-directed therapy, highlighting the need for vigilant monitoring.

  • Saved

1yr
Myeloid sarcoma and pathological fracture: a case report and review of literature - PubMed

Myeloid sarcoma and pathological fracture: a case report and review of literature - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37707761/

Myeloid sarcoma is a rare clinical entity that presents as an isolated proliferation of leukemic cells, concurrently with or at relapse of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), chronic...

Myeloid sarcoma, a rare complication of MDS, can lead to pathological fractures, as seen in a case involving trisomy 22. Chromosomal alterations, particularly in chromosomes 9 and 22, require careful management.

  • Saved

1yr
Williams-Beuren syndrome in pediatric T-cell acute lymphoblastic leukemia: A rare case report and review of literature - PubMed

Williams-Beuren syndrome in pediatric T-cell acute lymphoblastic leukemia: A rare case report and review of literature - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38363891/

To the best of our knowledge, this is the first reported case of WBS in T-cell acute lymphoblastic leukemia. We want to emphasize that the occurrence of leukemia in this...

This study presents the first reported case of T-cell acute lymphoblastic leukemia in a male child with Williams-Beuren syndrome, suggesting potential genetic associations and highlighting the need for further research.

  • Saved

1yr
Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review - PubMed

Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39105740/

Chronic neutrophil leukemia (CNL) is a rare and life-threatening disease. Cases of CNL combined with lymphoma are rare. Here, we report a case of CNL with T-acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)...

A 28-year-old with chronic neutrophil leukemia and T-ALL/LBL showed partial response to ruxolitinib and VICLP but relapsed; therapies including selinexor failed to achieve marrow remission. Early intervention is crucial.

  • Saved

1yr
Treatment of CLL: What’s next after covalent BTK inhibition?

Venetoclax is a treatment option for chronic lymphocytic leukemia (CLL) after progression or intolerance on a covalent Bruton tyrosine kinase (BTK) inhibitor. However, emergence of noncovalent BTK inhibitors raises concern of whether these agents may be more effective and better tolerated than venetoclax in this setting.

To help answer this question, an unanchored, matching-adjusted indirect comparison estimated the treatment effect of pirtobrutinib, a noncovalent BTK inhibitor, versus venetoclax after covalent BTK inhibitor therapy. This comparison used data from 146 patients with CLL naïve to venetoclax but previously treated with a covalent BTK inhibitor in a phase 1/2 trial (NCT03740529) and data from a trial of patients with CLL (n=91) receiving venetoclax monotherapy after a covalent BTK inhibitor (NCT02141282). Patients in the pirtobrutinib cohort were reweighted to match characteristics reported for venetoclax.

The comparison yielded objective response rates of 80.2% and 64.8% for pirtobrutinib and venetoclax, respectively (P=0.01). No meaningful differences were seen between pirtobrutinib and venetoclax for progression-free or overall survival rates. Each grade 3 or higher treatment-emergent adverse event was statistically significantly lower for pirtobrutinib (P<0.05 for all), except for pneumonia, but the rate of pneumonia was not significant.

These data suggest that noncovalent BTK inhibition provides greater response and lower toxicity than venetoclax after a covalent BTK inhibitor. Confirmation by comparative trials could lead to a paradigm shift.

What additional data are needed for your patients with CLL? What do you think the study design should look like?

  • 1yr
    I agree with my colleagues that a randomized blinded trial comparing the 2 is needed. otherwise, we will draw from our own experience or use cross trial comparison Show More
  • 1yr
    This is interesting and nice to have this in your back pocket for our patients who may not be venetoclax eligible for some reason. To really answer the question a study Show More

Show More Comments